Overview

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

Status:
Terminated
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the clinical trial is to assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic adenocarcinoma of the prostate, as well as to assess safety and tolerability of the study drug regimen and to evaluate secondary efficacy endpoints such as overall survival and duration of response.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute
The Methodist Hospital System
Collaborator:
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Androgen Antagonists
Androgens
Bicalutamide
Leuprolide
Paclitaxel